PDE4 inhibitor intermediate 1 is primarily used in the development of pharmaceuticals targeting inflammatory and autoimmune diseases. It plays a crucial role in synthesizing PDE4 inhibitors, which are effective in treating conditions like chronic obstructive pulmonary disease (COPD), asthma, psoriasis, and rheumatoid arthritis. By inhibiting the PDE4 enzyme, this intermediate helps reduce inflammation and modulate immune responses. Its application extends to research and development, where it aids in optimizing drug efficacy and safety profiles. Additionally, it is utilized in preclinical studies to explore potential therapeutic benefits for neurological disorders such as depression and multiple sclerosis, leveraging its anti-inflammatory properties.